COVID-19 前、中、后的甲状腺功能变化
这项队列观察研究纳入2020年3月9日至4月22日伦敦Imperial College Healthcare NHS Trust收治的456例疑似COVID-19成人患者,其中334例确诊、122例未确诊。大多数COVID-19患者(86.6%)入院时甲状腺功能正常,无显性甲状腺毒症;确诊者入院时TSH和FT4低于未确诊者,且较2019年基线降低,符合非甲状腺疾病综合征;随访时TSH恢复至基线。
要点
- 多数COVID-19患者入院时甲状腺功能正常,未见显性甲状腺毒症。
- 确诊者入院TSH和FT4低于未确诊者,且较基线降低。
- 存活者随访时TSH恢复至基线水平。
核心结论
- 大多数COVID-19患者表现为甲状腺功能正常。
- 观察到TSH和FT4轻度降低,符合非甲状腺疾病综合征。
- COVID-19存活者随访时甲状腺功能检查恢复至基线。
研究设计与样本
- 队列观察性研究,纳入2020年3月9日至4月22日伦敦Imperial College Healthcare NHS Trust收治的疑似COVID-19成人患者。
- 共456例患者,其中334例确诊COVID-19,122例未确诊;排除既存甲状腺疾病及缺失FT4或TSH测量者。
主要发现
- 86.6%的COVID-19患者入院时甲状腺功能正常,无显性甲状腺毒症。
- COVID-19患者入院时TSH和FT4低于非COVID-19患者。
- 在2019年有基线甲状腺功能数据的COVID-19患者中(TSH n=185,FT4 n=104),入院时TSH和FT4均较基线降低。
- 在随访、入院和基线均有TSH测量的COVID-19患者(n=55)中,随访时TSH恢复至基线。
临床怎么用
- COVID-19患者可出现轻度TSH和FT4降低,符合非甲状腺疾病综合征,多数甲状腺功能正常。
- 存活者随访时甲状腺功能可恢复至基线,提示急性期改变多为暂时性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The effects of COVID-19 on the thyroid axis remain uncertain. Recent evidence has been conflicting, with both thyrotoxicosis and suppression of thyroid function reported. OBJECTIVE: We aimed to detail the acute effects of COVID-19 on thyroid function and determine if these effects persisted on recovery from COVID-19. DESIGN: A cohort observational study was conducted. PARTICIPANTS AND SETTING: Adult patients admitted to Imperial College Healthcare National Health Service Trust, London, UK, with suspected COVID-19 between March 9 to April 22, 2020, were included, excluding those with preexisting thyroid disease and those missing either free thyroxine (FT4) or thyrotropin (TSH) measurements. Of 456 patients, 334 had COVID-19 and 122 did not. MAIN OUTCOME MEASURES: TSH and FT4 measurements were recorded at admission, and where available, in 2019 and at COVID-19 follow-up. RESULTS: Most patients (86.6%) presenting with COVID-19 were euthyroid, with none presenting with overt thyrotoxicosis. Patients with COVID-19 had a lower admission TSH and FT4 compared to those without COVID-19. In the COVID-19 patients with matching baseline thyroid function tests from 2019 (n = 185 for TSH and 104 for FT4), TSH and FT4 both were reduced at admission compared to baseline. In a complete case analysis of COVID-19 patients with TSH measurements at follow-up, admission, and baseline (n = 55), TSH was seen to recover to baseline at follow-up. CONCLUSIONS: Most patients with COVID-19 present with euthyroidism. We observed mild reductions in TSH and FT4 in keeping with a nonthyroidal illness syndrome. Furthermore, in survivors of COVID-19, thyroid function tests at follow-up returned to baseline.
引用
- Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19. J Clin Endocrinol Metab. 2021. PMID: 33180932. doi:10.1210/clinem/dgaa830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。